CD46 and cancer: High levels of membrane-bound complement-inhibitory molecules CD46, CD55, and CD59 are associated with resistance to therapeutic mAb in various cancers.28–32 The levels of all three of these proteins were higher in PEL lines compared to Daudi although there was some variation among the lines (Figure 3b; supplemental Figures 2B and 2C).